AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06100926 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: software
Description: virtual reality scene
Study NCT05409131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnipod 5 System
Description: Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes.
Study NCT05369585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-63
Description: 5-g per day dose of TOTUM-63 supplement, a mix of 5 plant extracts. Daily dose for 8 weeks followed by a 4 weeks follow-up period without supplementation.
Study NCT05957107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Description: The drug was administered once every 4 weeks.
Study NCT06140615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound of lungs
Study NCT05649631 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium
Description: 50 IHA patients were randomized into two groups with low sodium (50mmol/d) and normal sodium (100mmol/d) without potassium supplement. A 14 days dietary intervention was performed respectively to compare the changes in blood pressure (BP) and serum potassium in two groups.
Study NCT05888207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
Study NCT05888207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
Study NCT05614999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy training curriculum
Description: Eight sessions training in endoscopic tip control using Varix trainer model I.
Study NCT06458686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit D
Description: Vitamin D is a fat soluble vitamin used for the treatment of many diseases.
Study NCT06458686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a non drug formulation
Study NCT04997252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: apalutamide as neoadjuvant therapy
Study NCT05104437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covid-19 vaccine (0-1-4 schedule)
Description: Subjects receive the booster vaccine 3 months after the second dose.
Study NCT05104437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covid-19 vaccine (0-1-6 schedule)
Description: Subjects receive the booster vaccine 5 months after the second dose.
Study NCT05005975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117
Study NCT05846516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSV-GP154
Description: Injection
Study NCT05846516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP150
Description: Injection
Study NCT05279326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual SMAs
Description: 18 weeks lifestyle approach for type 2 diabetes program: Session 1 (week 0): Introduction; Session 2 (week 3): Behaviour change process; Session 3 (week 6): Medical nutrition therapy recommendations - Part 1; Session 4 (week 9): Medical nutrition therapy recommendations - Part 2; Session 5 (week 12): Medical physical Activity recommendations; Session 6 (week 15): Smoking cessation: tobacco and E-cigarettes; Session 7 (week 18): Diabetes distress.
Study NCT04745780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol, D-chiro-inositol, Gymnema sylvestre, Zinc and Alpha-lactalbumin
Description: Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months
Study NCT04745780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Two-times daily on an empty stomach, for 6 months
Study NCT05801354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turmeric Gel
Description: Turmeric gel will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
Study NCT05801354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
Study NCT05086120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eCARIBOU
Description: A 16 week remote electronically deliver Integrated Care Pathway (ICP) for adolescents (13-18 years old) with Major Depressive Disorder (MDD).
Study NCT05846516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP152
Description: Injection
Study NCT05846516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Infusion
Study NCT04994769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epitomee Capsule
Description: Epitomee Capsule combined with lifestyle counseling.
Study NCT05487443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors
Description: Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
Study NCT05318729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration tool
Description: Therapeutic mini massager for scar management, desensitization, muscle stimulation, oral stimulation and sensory re-education. Seek pain relief for sore achy muscles, tendons or bones.
Study NCT04686448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-ketamine
Description: patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
Study NCT06431360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperthermia
Description: hyperthermia (using a heater, 44℃for 15 min)
Study NCT05097183 — intervention group
Intervention type: PROCEDURE
Intervention: Accurate Commissural Alignment (ACA)
Description: Software based, computed tomography analysis that allows planification of accurate commissural alignment of TAVR by inserting the delivery system in a patient-specific degree of rotation.
Study NCT05426655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self management
Description: The program will consist of 3 sessions in which everything related to pain and its management will be explained. In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power Point presentation. In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle. A meditation session will also be held. In the third and last workshop, the game the painometer will be played and a meditation session will be held.
Study NCT06529198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroGyn Genital Neuromodulation System
Description: Genital Neuromodulation
Study NCT05302284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.0 mg/kg IV every 2 weeks
Study NCT05302284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg IV every 2 weeks
Study NCT05302284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle
Study NCT05302284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 70mg/m2 IV infusion on Day 1 of every 3 week cycle
Study NCT05302284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=4.5, IV infusion on Day 1 of every 3 week cycle
Study NCT05626010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen 1g iv dripping at end of surgery
Study NCT05626010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen 1g iv dripping at end of surgery
Study NCT05626010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen 300mg iv dripping at end of surgery
Study NCT06101966 — intervention group
Intervention type: RADIATION
Intervention: external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)
Description: Radical RT consisted of external pelvic beam radiotherapy (EBRT) and individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT).Cisplatin-based concurrent chemoradiotherapy (CCRT) was recommended for CC patients unless for economic status, age consideration and patients' desires.
Study NCT04686448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-fentanyl
Description: patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
Study NCT05201287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIA Disc NP
Description: VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
Study NCT04380831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT
Study NCT04380831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Undergo HSCT
Study NCT04380831 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo TBI using IMRT
Study NCT04380831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI using IMRT
Study NCT06161740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle strengthening
Description: The study involved adults aged 18 to 59 diagnosed with COVID-19 in the past year, experiencing mild or moderate symptoms, dyspnea, and either sedentary or engaging in physical exercise at least twice a week. Excluded were those with certain medical conditions. The participants were divided into two groups: one focused on global muscle strengthening (GF), and the other on low-intensity aerobic training with global muscle strengthening (GAF). The study assessed various parameters, including BMI, quality of life, aerobic capacity, dyspnea, and muscle strength. The sessions varied in duration and intensity. Volunteers were recruited from a clinic in Ubá-MG and randomly assigned to groups. The study aimed to evaluate the impact of the interventions on post-COVID-19 recovery.
Study NCT06161740 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle strengthening
Description: The study involved adults aged 18 to 59 diagnosed with COVID-19 in the past year, experiencing mild or moderate symptoms, dyspnea, and either sedentary or engaging in physical exercise at least twice a week. Excluded were those with certain medical conditions. The participants were divided into two groups: one focused on global muscle strengthening (GF), and the other on low-intensity aerobic training with global muscle strengthening (GAF). The study assessed various parameters, including BMI, quality of life, aerobic capacity, dyspnea, and muscle strength. The sessions varied in duration and intensity. Volunteers were recruited from a clinic in Ubá-MG and randomly assigned to groups. The study aimed to evaluate the impact of the interventions on post-COVID-19 recovery.
Study NCT05827783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of Bee Buzzy
Description: Implementation of Bee Buzzy It is defined as the use of a device called Bee Buzzy, which applies cold and vibrates in the form of a toy bee, by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this application, the researcher puts the Bee Buzzy device on the child's arm just above the area from which blood was taken, and remains attached to the arm during the phlebotomy procedure. This device applies cold and vibrates. Pain and fear during the procedure are evaluated by the researcher, the nurse, and the child's parent.
Study NCT05827783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of Puppet Zuzu
Description: Implementation of puppet zuzu It is defined as the use of a puppet that is seized and made to talk by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this practice, a puppet is seized by the researcher and made to talk, and the child's attention is tried to be drawn. While this procedure is in progress, the researcher, the nurse, and the child's parent evaluate the pain and fear during the procedure.
Study NCT06040957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate injection
Description: single intra-articular injection of Bone Marrow aspirate concentrate derived from the patient's iliac crest
Study NCT06040957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intra-articular injection of Minimally manipulated adipose tissue
Description: single intra-articular injection of Minimally manipulated adipose tissue derived from the patient's abdominal adipose tissue
Study NCT05380830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tied deep-Water Running
Description: 4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.
Study NCT05380830 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tied deep-Water Running
Description: 4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.
Study NCT06369337 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: The physical function variables will be analyzed through the Medical Research Council (MRC) and Functional Status Score (FSS), as well as swallowing function variables through the Volume-Viscosity Swallow (VVS-T) and Functional Oral Intake Scale scales. (FOIS) and Gugging Swallowing Screen (GUSS). The ecographic measurements will be made of the thickness and echogenicity of the submental and tonue muscles, as well as hyolaryngeal kinematics. These measurements will be performed 48 hours from the start of the orotracheal intubation episode, 7 days and 14 days of mechanical ventilation. To enable the correlation of clinical and ultrasound variables, one more independent measurement will be performed within the first 24 hours after authorization of oral tolerance in the patient.
Study NCT05035485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: A rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
Study NCT05035485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: A rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
Study NCT05163379 — intervention group
Intervention type: OTHER
Intervention: MOBILIZATION
Description: EARLY MOBILIZATION OF INTUBE PATIENTS AND ITS EFFECTS OF MOBILIZATION
Study NCT05344443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: A dual orexin antagonist
Study NCT05344443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo that looks and tastes like Lemborexant tablets
Study NCT04968249 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational Cohort to understand risk factors for early COPD.
Study NCT06549842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The intervention for this study is the dose of heparin. Patients randomized to group 1 will receive a heparin dose of 50U/kg and those in group 2 will receive a lower dose of heparin at 25U/kg. Recovery period for group 1 would be 2 hours whereas for group 2 would be 1 hour.
Study NCT06549842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: The intervention for this study is the dose of heparin. Patients randomized to group 1 will receive a heparin dose of 50U/kg and those in group 2 will receive a lower dose of heparin at 25U/kg. Recovery period for group 1 would be 2 hours whereas for group 2 would be 1 hour.
Study NCT06028269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone playing a sound
Description: A sound will be played from a portable device (smartphone) during movement
Study NCT06541535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid resuscitation with isotonic saline only
Description: Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers
Study NCT06152224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Leva Pelvic Health System
Description: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage.
Study NCT06541535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation with Ringer Lactate
Description: Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers
Study NCT06545734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Ischemic Post-conditioning
Description: After thrombectomy, the balloon was inflated to a pressure of no more than 4 atm at the occlusion site to block blood flow for 2 minutes, as confirmed by angiography. The balloon was then deflated, allowing blood flow to resume for 2 minutes. These steps were repeated four times.
Study NCT06545734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular therapy
Description: Thrombectomy alone.
Study NCT06545734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Description: Thrombectomy alone.
Study NCT05099328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recast Therapy
Description: Recast therapy is when a interventionist uses the child's own productions as a platform for restating or recasting the child's speech with corrections or alterations to focus on a particular syntax target.
Study NCT05099328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Syntax Stories
Description: Syntax stories are specially constructed stories read verbatim designed to teach a syntax target.
Study NCT06152224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Leva Pelvic Health System
Description: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage.
Study NCT04780204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Tenofovir Alafenamide 25 mg oral once daily
Study NCT05378945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate Nasal Spray
Description: Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
Study NCT05378945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days